Neoprobe has announced results from its Lymphoseek (tilmanocept) NEO3-09 study.
The Phase III clinical study enrolled 150 subjects with either breast cancer or melanoma within the intent-to-treat (ITT) population, and showed that Lymphoseek significantly detected all lymph nodes.
The NEO3-09 study highlighted Lymphoseek’s superior performance in intraoperative lymphatic mapping, a procedure in which lymph nodes are identified for biopsy to assess for the presence of tumour, compared to the use of vital blue dye.
Lymphoseek met all primary and secondary endpoints of the NEO3-09 study.
Related
Dr Vernon Sondak, chief of the oncology division at H Lee Moffitt Cancer Center and Research Institute, said Lymphoseek provided clinically meaningful advantages over blue dyes, and was found to be safe and well-tolerated.
Lymphoseek also exhibited superior performance in detecting lymph nodes containing cancer.
Related Companies
